Form 8-K - Current report:
SEC Accession No. 0001558370-24-012941
Filing Date
2024-09-23
Accepted
2024-09-23 07:35:21
Documents
15
Period of Report
2024-09-23
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K qure-20240923x8k.htm   iXBRL 8-K 34554
2 EX-99.1 qure-20240923xex99d1.htm EX-99.1 17698
3 GRAPHIC qure-20240923xex99d1001.jpg GRAPHIC 5715
  Complete submission text file 0001558370-24-012941.txt   182354

Data Files

Seq Description Document Type Size
4 EX-101.SCH qure-20240923.xsd EX-101.SCH 3264
5 EX-101.LAB qure-20240923_lab.xml EX-101.LAB 15216
6 EX-101.PRE qure-20240923_pre.xml EX-101.PRE 9966
17 EXTRACTED XBRL INSTANCE DOCUMENT qure-20240923x8k_htm.xml XML 4647
Mailing Address PAASHEUVELWEG 25A AMSTERDAM P7 1105 BP
Business Address PAASHEUVELWEG 25A AMSTERDAM P7 1105 BP 1-339-970-7000
uniQure N.V. (Filer) CIK: 0001590560 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36294 | Film No.: 241314643
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)